Sodium-Glucose Co-transporter 2 Inhibitor: A Perspective on Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus

Publisher： Jaypee Infomedia

ISSN： 2454-5996

Source： Hypertension Journal, Vol.2, Iss.3, 2016-07, pp. : 139-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium‐glucose co‐transporter‐2 inhibitors in the USA: A retrospective cohort study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 582-589

John Wiley & Sons Inc

Access to resources Recommend Favorite

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D   Wilding John PH  

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus

By Lamos Elizabeth M  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 6, 2013-06 ,pp. : 763-775

Informa Healthcare

Access to resources Recommend Favorite

Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 6, 2015-06 ,pp. : 591-598

John Wiley & Sons Inc

Access to resources Recommend Favorite

A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 1462-8902, Iss. 10, 2015-10 ,pp. : 984-993

John Wiley & Sons Inc

Access to resources Recommend Favorite